ProCE Banner Activity

Why Do Schizophrenia Patients Relapse and What Should We Do?

Slideset

This presentation reviews the risk factors for relapse in schizophrenia; the importance of medication adherence in prevention of relapse; the consequences of nonadherence to medication in schizophrenia; and the role of early intervention services and coordinated specialty care in patients with schizophrenia.

Released: March 22, 2022

Expiration: March 21, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Independent Educational Activity

Faculty Disclosure

Primary Author

John M. Kane, MD

Co-Director, Institute of Behavioral Science
Feinstein Institutes for Medical Research
Professor, Psychiatry and Molecular Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
New York, New York

John M. Kane, MD, has disclosed that he has received funds for research support from H. Lundbeck, Janssen, and Otsuka; has received consulting fees from Alkermes, Allergan, Dainippon Sumitomo, H. Lundbeck, Intra-Cellular Therapies, Janssen, LB Pharmaceuticals, Lyndra, Merck, Neurocrine Biosciences, Otsuka, Reviva, Roche, Saladex, Sunovion, Takeda, and Teva; has ownership interest in LB Pharmaceuticals, Merck, Minerva, and North Shore Therapeutics; and has received fees for non-CME/CE services from Dainippon Sumitomo, H. Lundbeck, Janssen, and Otsuka.